01—Abstract
Summary
Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Alnylam reported third-quarter 2025 results on October 30, 2025 that showed a sharp acceleration in its commercial business.
Total revenues were $1.249 billiona, up 149% year over year, and total net product revenues were $851 million, up 103% (99% at constant exchange rates). The growth was driven primarily by AMVUTTRA for ATTR-CM, which generated $685 million in Q3 net product revenue, up 165%. Total TTR net product revenues reached $724 million (+135%).
Collaboration revenue of $352 millionb was lifted by a $300 million Roche milestone tied to the first patient dosed in the ZENITH Phase 3 trial of zilebesiran. The company reported GAAP net income of $251 million (diluted EPS $1.84) versus a net loss in Q3 2024, and non-GAAP operating income of $476 million. Note that the quarter's GAAP results include a $300 million one-time milestone and a $39 million loss on convertible debt repurchase, so the underlying profitability trend should be read with that in mind.
Alnylam raised its full-year 2025 guidance. Total net product revenues are now expected at $2.95 billion to $3.05 billionc (up from $2.65 billion to $2.80 billion), and TTR net product revenues at $2.475 billion to $2.525 billion. The company also reiterated its goal of achieving non-GAAP operating profitability for 2025.
Balance sheet activity was significant: Alnylam issued $661 milliond of 0.00% convertible notes due 2028, repurchased $638 million of its 1.00% notes due 2027, and entered into a $500 million revolving credit facility. Cash and marketable securities totaled $2.7 billion at quarter-end. Investors should also note that the company disclosed a subpoena from the U.S. Attorney's Office for the District of Massachusetts concerning government price reporting for several of its products, including fee and discount arrangements with distributors.
The outcome and potential financial impact of that inquiry are not yet known. On the pipeline side, the company began the TRITON-PN Phase 3 trial of nucresiran in hATTR polyneuropathy, with topline results expected in 2028, and the ZENITH Phase 3 cardiovascular outcomes trial of zilebesiran is underway.
Regeneron's cemdisiran met its primary endpoint in the Phase 3 NIMBLE trial in generalized myasthenia gravis. Management plans to initiate a Phase 2 trial of mivelsiran in Alzheimer's disease in Q4 2025.
02—Key points
Key Highlights
- Total revenues of $1.249 billion, up 149% year over year, including a $300 million Roche milestone recognized in September 2025 for the first ZENITH patient dosed.
- Total net product revenues of $851 million (+103%), led by AMVUTTRA at $685 million (+165%) and total TTR revenues of $724 million (+135%).
- GAAP net income of $251 million ($1.84 diluted EPS) versus a net loss of $112 million in Q3 2024; non-GAAP operating income of $476 million.
- Full-year 2025 total net product revenue guidance raised to $2.95–$3.05 billion (about 10% increase at midpoint); TTR guidance raised to $2.475–$2.525 billion.
- Refinanced convertible debt: issued $661 million of 0.00% notes due 2028 and repurchased $638 million of 1.00% notes due 2027, with a $39 million inducement loss; also added a $500 million revolver.
- Received a subpoena from the U.S. Attorney's Office for the District of Massachusetts regarding government price reporting and distributor fee and discount arrangements for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI.
- Pipeline progress: TRITON-PN Phase 3 (nucresiran) initiated with topline data expected in 2028; ZENITH Phase 3 (zilebesiran) underway; Regeneron's cemdisiran met its Phase 3 NIMBLE endpoint.
03—Questions
Frequently Asked Questions
How strong was the AMVUTTRA launch in ATTR-CM during Q3 2025?
AMVUTTRA generated $685 million of net product revenue in Q3 2025, up 165% year over year (162% at constant currency). Management said ATTR-CM patient demand roughly doubled from Q2 to Q3, with first-line use in new-to-treatment patients and most patients paying $0 out of pocket. Q3 was only the company's second full quarter of the ATTR-CM launch.
Is Alnylam now consistently profitable, and how much of Q3 earnings was one-time?
Q3 2025 GAAP net income was $251 million, but it was boosted by a $300 million Roche milestone recognized in September, which is non-recurring in nature. Non-GAAP operating income was $476 million, excluding $108 million of stock-based compensation. Investors should evaluate the run-rate profitability excluding this milestone, and the company's full-year 2025 non-GAAP operating profitability target is reiterated in the guidance.
What does the Department of Justice-related subpoena mean for investors?
The filing discloses a subpoena from the U.S. Attorney's Office for the District of Massachusetts seeking documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI, including certain fee and discount arrangements with distributors. The filing does not quantify any potential liability, and the outcome is uncertain. Investors should monitor future 10-Q disclosures for any accrual, scope expansion, or settlement.
Why did the company change its capital structure, and what are the implications?
Alnylam issued $661 million of 0.00% convertible notes due 2028 and used proceeds mainly to repurchase $638 million of its 1.00% notes due 2027, paying about $1.1 billion in cash for those repurchases and incurring a $39 million inducement loss. The 0.00% coupon lowers near-term interest cost, and the new $500 million revolver adds liquidity. Total cash and marketable securities declined to $2.7 billion from $2.9 billion at June 30, 2025.
What are the key upcoming catalysts?
Near-term catalysts include presentation of new HELIOS-B cardiac MRI data at AHA (November 7–10, 2025), the planned start of a Phase 2 mivelsiran trial in Alzheimer's disease in Q4 2025, and Regeneron's planned Q1 2026 U.S. regulatory submission for cemdisiran in generalized myasthenia gravis. Longer-term, topline TRITON-PN results are expected in 2028, and ZENITH Phase 3 outcomes for zilebesiran are a major multi-year event.
04—Continue